Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSEPH L IZZO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1750481065
CMS profile
306306
Location
BUFFALO, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$4,489.76

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $4,000.00 1
Travel and Lodging $258.77 1
Food and Beverage $230.99 4

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Clarus Therapeutics Inc. $4,489.76 6

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSEPH L IZZO

NPI 1750481065 · CMS profile ID 306306

Allopathic & Osteopathic Physicians / Internal Medicine

BUFFALO, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750481065?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSEPH L IZZO, NPI 1750481065, CMS profile ID 306306. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750481065?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JOSEPH L IZZO, NPI 1750481065, CMS profile ID 306306. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750481065?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JOSEPH L IZZO, NPI 1750481065, CMS profile ID 306306, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1750481065?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $4,489.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Clarus Therapeutics Inc. $4,000.0001/04/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750557347 CMS
Clarus Therapeutics Inc. $30.0001/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750557351 CMS
Clarus Therapeutics Inc. $50.0001/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750557357 CMS
Clarus Therapeutics Inc. $42.7701/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750557361 CMS
Clarus Therapeutics Inc. $108.2201/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750557365 CMS
Clarus Therapeutics Inc. $258.7701/03/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750557369 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,185.67 1
PY2020 $4,489.76 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020
Generated from
OP_DTL_GNRL_PGYR2020_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $262,437.61 10
PY2024 Principal investigator $132,484.23 7
PY2023 Recipient $1,198.58 1
PY2023 Principal investigator $248,940.80 9
PY2022 Principal investigator $275,671.01 9
PY2021 Principal investigator $165,772.89 19
PY2020 Principal investigator $259,837.46 36
PY2019 Principal investigator $221,377.65 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

33 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,034.89 12/31/2019 Non-covered Recipient Entity
Research Found Of State Univ
An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF) Short Title DETERMINE-reduced Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fraction No dispute reported 06/30/2026 684989972
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,976.54 12/31/2019 Non-covered Recipient Entity
Research Found Of Suny
An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF) Short Title DETERMINE-reduced Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fraction No dispute reported 06/30/2026 684990005
Principal investigator 1 AstraZeneca Pharmaceuticals LP $64.59 12/31/2019 Non-covered Recipient Entity
Research Found Of Suny
Forxiga HF-D1699C00001 HF rEF Outcome study No dispute reported 06/30/2026 684990009
Principal investigator 1 AstraZeneca Pharmaceuticals LP $788.26 12/31/2019 Non-covered Recipient Entity
Research Foundation Of State
An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF) Short Title DETERMINE-reduced Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fraction No dispute reported 06/30/2026 684990025
Principal investigator 1 AstraZeneca Pharmaceuticals LP $65.50 12/31/2019 Non-covered Recipient Entity
Research Foundation Of State
Forxiga HF-D1699C00001 HF rEF Outcome study No dispute reported 06/30/2026 684990027
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,352.35 12/31/2019 Non-covered Recipient Entity
Research Foundation Of Suny
An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF) Short Title DETERMINE-reduced Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fraction No dispute reported 06/30/2026 684990073
Principal investigator 1 AstraZeneca Pharmaceuticals LP $60.06 12/31/2019 Non-covered Recipient Entity
Research Foundation Of Suny
Forxiga HF-D1699C00001 HF rEF Outcome study No dispute reported 06/30/2026 684990075
Principal investigator 1 AstraZeneca Pharmaceuticals LP $827.08 12/31/2019 Non-covered Recipient Entity
Suny Heart Research Fund
An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF) Short Title DETERMINE-reduced Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fraction No dispute reported 06/30/2026 684992253
Principal investigator 1 AstraZeneca Pharmaceuticals LP $30.94 12/31/2019 Non-covered Recipient Entity
Suny Heart Research Fund
Forxiga HF-D1699C00001 HF rEF Outcome study No dispute reported 06/30/2026 684992257
Principal investigator 1 AstraZeneca Pharmaceuticals LP $876.58 12/31/2019 Non-covered Recipient Entity
Suny Research Dept Of Psychiatry
An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF) Short Title DETERMINE-reduced Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fraction No dispute reported 06/30/2026 684992269
Principal investigator 1 AstraZeneca Pharmaceuticals LP $60.97 12/31/2019 Non-covered Recipient Entity
Suny Research Dept Of Psychiatry
Forxiga HF-D1699C00001 HF rEF Outcome study No dispute reported 06/30/2026 684992271
Principal investigator 1 AstraZeneca Pharmaceuticals LP $30.03 12/31/2019 Non-covered Recipient Entity
The Research Foundation Of State University Of New York
Forxiga HF-D1699C00001 HF rEF Outcome study No dispute reported 06/30/2026 684993255
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,007.18 10/17/2019 Non-covered Recipient Entity
Research Foundation Of Suny
An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF) Short Title DETERMINE-reduced Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fraction No dispute reported 06/30/2026 684990045
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,014.88 09/17/2019 Non-covered Recipient Entity
Research Found Of State Univ
An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF) Short Title DETERMINE-reduced Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fraction No dispute reported 06/30/2026 684989967
Principal investigator 1 AstraZeneca Pharmaceuticals LP $24,856.98 09/17/2019 Non-covered Recipient Entity
Research Found Of Suny
An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF) Short Title DETERMINE-reduced Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fraction No dispute reported 06/30/2026 684989993
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,913.20 09/17/2019 Non-covered Recipient Entity
Research Foundation Of State
An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF) Short Title DETERMINE-reduced Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fraction No dispute reported 06/30/2026 684990017
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,401.45 09/17/2019 Non-covered Recipient Entity
Suny Heart Research Fund
An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF) Short Title DETERMINE-reduced Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fraction No dispute reported 06/30/2026 684992245
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,023.92 09/17/2019 Non-covered Recipient Entity
Suny Research Dept Of Psychiatry
An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF) Short Title DETERMINE-reduced Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fraction No dispute reported 06/30/2026 684992261
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,105.60 07/11/2019 Non-covered Recipient Entity
Research Found Of State Univ
An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) No dispute reported 06/30/2026 684989963
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,367.28 07/11/2019 Non-covered Recipient Entity
Research Foundation Of State
An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) No dispute reported 06/30/2026 684990015
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,050.32 07/11/2019 Non-covered Recipient Entity
Suny Heart Research Fund
An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) No dispute reported 06/30/2026 684992243
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,638.56 07/09/2019 Non-covered Recipient Entity
Research Found Of State University Of New York
An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) No dispute reported 06/30/2026 684989977
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,548.68 07/09/2019 Non-covered Recipient Entity
Research Foundation Of Suny
An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) No dispute reported 06/30/2026 684990039
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,181.37 06/27/2019 Non-covered Recipient Entity
Research Found Of Suny
An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) No dispute reported 06/30/2026 684989989
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,735.00 06/18/2019 Non-covered Recipient Entity
Research Foundation Of State
Forxiga HF-D1699C00001 HF rEF Outcome study No dispute reported 06/30/2026 684990021
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,292.00 06/18/2019 Non-covered Recipient Entity
Suny Heart Research Fund
Forxiga HF-D1699C00001 HF rEF Outcome study No dispute reported 06/30/2026 684992249
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,546.00 06/18/2019 Non-covered Recipient Entity
Suny Research Dept Of Psychiatry
Forxiga HF-D1699C00001 HF rEF Outcome study No dispute reported 06/30/2026 684992265
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,075.00 05/23/2019 Non-covered Recipient Entity
ERIE COUNTY MEDICAL CENTER
A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP ACTIVE CONTROLLED 8 WEEK STUDY TO EVALUATE THE EFFECT OF LCZ696 VERSUS ENALAPRIL ON CHANGES IN NT PROBNP AND SAFETY AND TOLERABILITY OF IN HOSPITAL INITIATION OF LCZ696 COMPARED TO ENALAPRIL IN HFREF PA No dispute reported 06/30/2026 640715999
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,697.00 03/05/2019 Non-covered Recipient Entity
Research Found Of Suny
Forxiga HF-D1699C00001 HF rEF Outcome study No dispute reported 06/30/2026 684989995
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,508.00 03/05/2019 Non-covered Recipient Entity
Research Foundation Of Suny
Forxiga HF-D1699C00001 HF rEF Outcome study No dispute reported 06/30/2026 684990049
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,254.00 01/29/2019 Non-covered Recipient Entity
The Research Foundation Of State University Of New York
Forxiga HF-D1699C00001 HF rEF Outcome study No dispute reported 06/30/2026 684993222
Principal investigator 1 Novartis Pharmaceuticals Corporation $35,583.44 01/01/2019 Non-covered Recipient Entity
ERIE COUNTY MEDICAL CENTER
PROSPECTIVE COMPARISON OF COMBINED ANGIOTENSIN NEPRILYSIN INHIBITION WITH LCZ696 RELATIVE TO ENALAPRIL ON CENTRAL AORTIC STIFFNESS AND VENTRICULAR VASCULAR COUPLING IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION No dispute reported 06/30/2026 640715995
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,410.00 01/01/2019 Non-covered Recipient Entity
ERIE COUNTY MEDICAL CENTER DEPARTMENT OF CARDIOLOGY
OBSERVATIONAL REGISTRY OF TREATMENT PATTERNS IN US HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION No dispute reported 06/30/2026 640716003